U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. For Industry
  3. FDA User Fee Programs
  4. Biosimilar User Fee Amendments
  5. Public Meeting on the Reauthorization of the Biosimilar User Fee Act (BsUFA) - 11/19/2020 - 11/19/2020
  1. Biosimilar User Fee Amendments

Public | Virtual

Event Title
Public Meeting on the Reauthorization of the Biosimilar User Fee Act (BsUFA)
November 19, 2020

Date:
November 19, 2020

DESCRIPTION/SUMMARY

The Food and Drug Administration (FDA or Agency) held a public meeting on the reauthorization of the Biosimilar User Fee Act (BsUFA) for fiscal years (FYs) 2023 through 2027. BsUFA authorizes FDA to collect user fees to support the process for the review of biosimilar biological products.  The current legislative authority for BsUFA expires in September 2022.  At that time, new legislation will be required for FDA to continue collecting user fees in future fiscal years. FDA begins the BsUFA reauthorization process by publishing a notice in the Federal Register requesting public input and holding a public meeting to hear stakeholder views as we consider the next BsUFA. For more background information or to submit comments, please see the Federal Register notice with assigned docket FDA-2015-N-3326.

WEBCAST

This meeting was held in virtual format only, at https://collaboration.fda.gov/bsufanov2020/. Registration was available at this link on Eventbrite.

The meeting recording can be accessed at https://collaboration.fda.gov/ptnqmlycvlft/.

EVENT POINT OF CONTACT

Emily Ewing, Emily.Ewing@fda.hhs.gov, Center for Drug Evaluation and Research, Food and Drug Administration

Back to Top